Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

2.1K

A new biomarker for Parkinson's disease?

Caroline H Williams-Gray1

  • 1John Van Geest Center for Brain Repair, University of Cambridge, UK, Cambridge, UK.

Movement Disorders : Official Journal of the Movement Disorder Society
|December 22, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

2.1K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K

Related Concept Videos

Neural Regulation01:37

Neural Regulation

44.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K

Articles linked to this work by shared authors, journal, and citation graph.

Personalised prediction of institutionalisation in Parkinson's: prognostic factor identification and model development and validation using IPD meta-analysis.

Parkinsonism & related disorders·2026

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Prognosis in Parkinson's Disease: An Individual Patient Data Meta-Analysis of Six European Incidence Cohorts.

Movement disorders : official journal of the Movement Disorder Society·2026

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

The Lancet. Neurology·2025

Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".

NPJ Parkinson's disease·2025

Apathy in Lewy Body Disorders: A Position Paper.

Movement disorders : official journal of the Movement Disorder Society·2026

Subthalamic Nucleus Deep Brain Stimulation Enhanced Long-Latency Reflex II in Parkinson's Disease Through Rapid Subthalamic-Cortical Modulation.

Movement disorders : official journal of the Movement Disorder Society·2026

Joint Risk Factor Combinations with Additive Interaction Increase the Risk of Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

COVID-19 Amplifies Sex-Specific Dopamine and Glial Responses in a Parkinson's Disease Mouse Model.

Movement disorders : official journal of the Movement Disorder Society·2026

Early Longitudinal Brain Network Changes in Huntington's Disease Before Clinical Motor Onset.

Movement disorders : official journal of the Movement Disorder Society·2026

Expanded ATXN3 CAG Repeat is Stable in Human Purkinje Cells.

Movement disorders : official journal of the Movement Disorder Society·2026

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Cureus·2026

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Frontiers in endocrinology·2026

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Canadian journal of kidney health and disease·2026

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Frontiers in pharmacology·2026

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Frontiers in molecular neuroscience·2026

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Therapeutic advances in neurological disorders·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us